SGMO
SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS, INC (SGMO) has 12 SEC Form 4 filings (17 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: May 27, 2026.
Insiders have net sold $107K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Alexander D. Macrae Ch.B
- Employees:183
- HQ:Richmond, CA, US
- IPO:2000-04-06
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$107K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
Dubois-Stringfellow NathalieFirst filing | SVP-CHIEF DEVELOPMENT OFFICER | Sale | 345,942 | $89K | Apr 23 | SEC ↗ |
Davis Gregory DFirst filing | Head of Research & Technology | Sale | 69,827 | $18K | Apr 23 | SEC ↗ |
Related companies
SANGAMO THERAPEUTICS, INC is in the Healthcare sector.